There is now increasing evidence that essential hypertension is a serious risk factor for renal insufficiency. It has been known for many years that malignant essential hypertension rapidly causes deterioration of kidney function. This can be prevented by treatment with antihypertensive drugs. Mild-to-moderate essential hypertension causes significant renal function impairment only after a number of years. There are now data suggesting that the decline of renal function caused by
Introduction
Cerebrovascular accidents and coronary heart disease are frequent and well recognised sequelae of arterial hypertension. 1 The relationship between hypertension and disturbances of renal function is less clear. This is particularly true for mild essential hypertension.
Assessment of renal function in hypertensive patients
The most accurate way to determine renal function is measurement of the glomerular filtration rate (GFR). This is also true for the assessment of renal function in patients with hypertension. A much simpler procedure is to measure serum creatinine concentrations. When doing so one should, however, be aware of confounding factors which may make serum creatinine levels an unreliable measure for the estimation of kidney function. At equilibrium with constant serum levels, the production of an endogenous substance like creatinine equals its elimination. In this situation, the production of creatinine is equal to the product of GFR and the serum creatinine concentration provided that creatinine is exclusively eliminated by glomerular filtration. Then the serum level of creatinine is equal to its production divided by GFR. If GFR decreases concomitantly with a production of creatinine, this will result in unchanged serum levels of the substance. This situation frequently occurs in elderly patients in whom muscle mass as the main determinant of creatinine production is diminished and at the same time GFR is decreased. In these patients, totally normal serum creatinine concentrations may be meas- ured although GFR is considerably decreased. Under these circumstances, estimation of serum creatinine concentrations seriously underestimates the degree of renal impairment. Therefore, measurements of GFR are more reliable than the determination of serum creatinine levels for the assessment of renal function.
The gold standard for measurement of GFR is the classical inulin clearance. This method, however, requires a sensitive procedure for measuring inulin plasma and urinary concentrations. Furthermore, exact timed urine collections are necessary. This may be a problem particularly in elderly patients with difficulties in voiding. Therefore, these days isotope methods are increasingly used, for instance the 51 Cr-EDTA procedure. This method allows the estimation of GFR from the slope of the 51 Cr levels in plasma after intravenous injection of 51 Cr-EDTA. The substance, however, is not exclusively eliminated via the kidneys. About 5 ml/min of the total clearance of 51 Cr-EDTA is due to extrarenal elimination. This extrarenal clearance is fairly constant at different degrees of renal impairment. Therefore, it quantitatively becomes more relevant the lower GFR is. A simple and frequently used method for the estimation of GFR is the determination of creatinine clearance using urine collection periods ranging from 12-24 h. Creatinine, however, is not exclusively excreted by glomerular filtration. Part of the substance is excreted into urine by tubular secretion. One should bear in mind that the tubular secretion of creatinine may be altered by drugs, for instance by nifedipine. Such an influence always has to be excluded when creatinine clearance is used as a measure of GFR.
Renal function in essential hypertension
Essential hypertension appears to be a frequent cause of end-stage renal failure. According to the US Renal Data System 1991, diabetes mellitus and essential hypertension were the two major diagnostic categories of patients reaching terminal renal failure in 1987 with increasing frequency since 1981. 2 These data show that chronic glomerulonephritis in 1987 was less frequently the course of end-stage renal failure than was essential hypertension. It should, however, be considered that hypertensive nephropathy was diagnosed clinically in uremic patients with a history of prolonged hypertension, no or low-grade proteinuria and without evidence of primary renal disease. Therefore, the frequency of essential hypertension may have been overestimated.
The relationship between essential hypertension and renal function impairment became evident from observations with malignant hypertension. 3 At a time when the first anti-hypertensive drugs became available, all 24 patients with malignant hypertension who refused drug treatment died within 3 years. In 33% the cause of death was uremia, in another 33% a cerebrovascular accident. There was a striking improvement of prognosis in another 73 patients with malignant hypertension who received anti-hypertensive agents. Within 3 years, 56% of these patients died. The cause of death was uremia in 16%, a cerebrovascular accident in 19%. 3 These observations were made at a time when haemodialysis was not available in most hospitals. One may conclude from this and a number of similar studies that malignant essential hypertension causes serious renal impairment. Treatment with antihypertensive drugs decreases the risk of renal failure.
This situation is less clear in patients with mildto-moderate essential hypertension. In a study by Perneger et al, 4 1399 middle-aged residents had their blood pressure (BP) measured during a cancer screening campaign in 1974. In the same subjects, BP measurement was repeated in the years 1986-1989 in an atherosclerosis risk factor study. Concomitantly with the second BP measurement, serum creatinine levels of the subjects were determined. The risk to develop elevated serum creatinine levels in 1986-1989 increased progressively with higher diastolic BP values measured in 1974. This risk was more than three times higher in men and approximately two times higher in women who had diastolic BP values ranging from 91-118 mm Hg compared with persons having diastolic BP below 79 mm Hg. The association between systolic BP values measured in 1974 and elevated serum creatinine concentrations was less strong. There was no significant relation between serum creatinine levels and BP values measured in 1986-1989. The strength of this study is mitigated by the absence of information on serum creatinine levels in 1974. It is conceivable that subjects with elevated serum creatinine concentrations in 1974 also had increased BP values. In an 8-year follow-up study of 56 patients with essential hypertension and 59 normotensive controls, the hypertensive patients had a greater rate of decline in renal function than normotensive subjects. 5 At entrance into the study, both groups of subjects had no signs of renal parenchymal disease. 5 Recently, data from a large community-based health examination programme were published. 6 In 1983, 107 192 subjects had a health examination including measurement of BP in Okinawa (Japan). Of these, a total of 193 developed terminal renal failure requiring dialysis within 10 years. The incidence of end-stage renal failure increased continuously with rising diastolic BPs measured in 1983. A similar-though not as pronounced-rise of incidence of end-stage renal failure occurred with increasing systolic BP values.
Taken together, there is now increasing evidence that long-lasting mild-to-moderate hypertension has a deleterious effect on kidney function.
Until now, it has not been proven that in patients with mild-to-moderate essential hypertension antihypertensive treatment prevents the decline of renal function. In the Australian Therapeutic Trial in Mild Hypertension, 7 two patients of the placebo group had a rise of serum creatinine levels to Ͼ2 mg/dl as compared with one patient in the group treated with anti-hypertensive drugs. In both groups, serum creatinine levels had been normal at entrance into the study. In the Hypertension Detection and Follow-up Program, 10 940 hypertensive subjects were followed up for 5 years. If baseline serum creatinine level was Ͻ1.5 mg/dl at entrance into the study, only a few patients had a rise of serum creatinine concentrations to levels Ͼ2 mg/dl during the observation period; there was no difference between patients who received stepped care and those with referred care. 8 Considerably more hypertensives developed serum creatinine levels у2 mg/dl during the treatment period if serum creatinine concentration ranged from 1.5-1.69 mg/dl at entrance. This was true for 113 patients in the stepped care group and 226 patients in the referred care group. The difference is statistically significant (P = 0,01). One should, however, keep in mind that the data published by Shulmann et al 8 are based on a retrospective analysis of subgroups. Himmelmann et al 9 treated a total of 257 patients with essential hypertension for 24 months. The patients were randomised to receive either the angiotensin-converting enzyme (ACE) inhibitor cilazapril or the beta-receptor blocker atenolol. Initially, the decline in GFR was smaller with cilazapril than with atenolol. However, after 24 months the difference between the atenolol group and the cilazapril group were not statistically significant.
Renal function in secondary forms of hypertension
BP starts to rise in patients with diabetes mellitus as soon as diabetic nephropathy develops. Diabetic nephropathy results in serious renal impairment frequently requiring dialysis. It is well known that effective treatment of hypertension slows the progression of renal function disturbances in patients with diabetic nephropathy. 10 It has also been demonstrated that ACE inhibitors are more effective in preventing progression of renal failure in these patients than other anti-hypertensive drugs. 11 Several forms of chronic glomerulonephritis are frequently associated with hypertension. This is particularly true for mesangioproliferative glomerulonephritis and for IGA-nephritis. BP increases concomitantly with the decrease in renal mass. Antihypertensive treatment has been shown to slow the progression of renal failure in such patients. 12 As in patients with diabetic nephropathy, ACE inhibitors are particularly effective in this respect. 12 
